Introduction of LACRIFILL Canalicular Gel
Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., has recently made a significant breakthrough in the treatment of dry eye. The introduction of LACRIFILL Canalicular Gel is transforming how ophthalmologists combat this common yet often debilitating condition. During the American Academy of Ophthalmology (AAO) 2024 event, the company showcases this novel therapy to leading experts in the field.
Unveiling LACRIFILL at AAO 2024
With extensive research and development, LACRIFILL Canalicular Gel is poised to provide effective relief for dry eye sufferers. This unique gel, which is FDA-cleared, functions by temporarily occluding tear drainage through the canalicular system. The simple in-office procedure ensures that patients benefit from their natural tears, providing essential hydration to the eyes.
Personalized Treatment Approach
Unlike conventional therapies, LACRIFILL Canalicular Gel is customized to meet the specific needs of each patient. Administering this innovative therapy allows for a complete fill within the canalicular system, delivering continuous moisture for an extended period—up to six months according to clinical findings.
Impact on Practices and Patients
Phil Gioia, President of Nordic Pharma’s U.S. operations, expressed enthusiasm about their presence at AAO, emphasizing the importance of sharing their advancements in dry eye treatments with the medical community. He noted that the collaboration with Nordic Pharma’s esteemed Medical Advisory Board and recent clinical findings in reputable journals underscores the therapy's potential to uplift patient care quality.
Clinical Efficacy and Research
The effectiveness of LACRIFILL Canalicular Gel has been highlighted in the October issue of the Journal of Cataract and Refractive Surgery. The study, which involved numerous esteemed authors in the field, validates that this cross-linked hyaluronic acid gel is both safe and effective for lacrimal occlusion. Clinically significant improvements in dry eye symptoms have been documented, showcasing the gel’s sustained benefits over six months.
Patient Experiences with LACRIFILL
According to Dr. Neel R. Desai from the Eye Institute of West Florida, the ease of administering LACRIFILL Canalicular Gel and the immediate relief it provides have made it an integral part of his practice for managing dry eye. As a trusted expert in the field, Dr. Desai's endorsement highlights the benefits that this therapy can offer to patients.
Engagement at the AAO Conference
Attendees at AAO are encouraged to visit Nordic Pharma's booth #4062 for an enlightening Q&A session led by Kevin J. Corcoran, with a focus on LACRIFILL Canalicular Gel’s reimbursement landscape. Additionally, the event serves as an opportunity for healthcare professionals to place orders and directly engage with representatives.
Commitment to the Community
Nordic Pharma's active participation at AAO extends beyond just product presentations; they are also proud to sponsor the Women In Ophthalmology Awards Ceremony. This commitment reflects their dedication to supporting the advancements of women in the field and emphasizes their mission to enhance patient care.
Company Background
Nordic Group B.V. is not just a pharmaceutical company; it is a visionary enterprise driven by a profound mission. With a focus on specialty products in eye care, rheumatology, and women's health, the company is building a legacy that transcends geographical boundaries. Their strategic acquisitions and targeted developments ensure that they remain at the forefront of innovation in the global healthcare landscape.
About Nordic Pharma, Inc.
Nordic Pharma, Inc. serves as the U.S. operations arm of Nordic Group B.V. Collaborating with established biopharmaceutical partners, Nordic Pharma is strategically positioned to leverage its deep-rooted expertise to bring groundbreaking therapies to the U.S. market. Their emphasis on state-of-the-art techniques ensures that they will continue to meet the evolving needs of healthcare providers and their patients.
Frequently Asked Questions
What is LACRIFILL Canalicular Gel?
LACRIFILL Canalicular Gel is a novel therapy developed to temporarily occlude tear drainage, helping to alleviate symptoms of dry eye by utilizing the patient’s natural tears.
How is LACRIFILL administered?
This therapy is administered through a straightforward in-office procedure that ensures the canalicular system is completely filled, providing relief for up to six months.
What are the main benefits of LACRIFILL Canalicular Gel?
The gel offers significant hydration relief for dry eye patients, is safe to use, and is backed by clinical studies demonstrating its efficacy and sustained results.
Where can I learn more about LACRIFILL?
More information, including ordering details, can be found at lacrifill.com, where prospective patients and healthcare providers can explore the therapy further.
Who is Nordic Pharma?
Nordic Pharma, Inc. is a subsidiary of Nordic Group B.V. focused on developing and commercializing pharmaceutical products, particularly in specialty areas like eye care.
